FINWIRES · TerminalLIVE
FINWIRES

ASX:PYC

9 stories mentioning ASX:PYCUpdated just now

Every FINWIRES story that references ASX:PYC, newest first.

Asia

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Friday.4DMedical (ASX:4DX): -8%, AU$4.25ResMed (ASX:RMD): -6%, AU$29.55EchoIQ (ASX:EIQ): -6%, AU$1.46Phylogica (ASX:PYC): -5%, AU$2.02DroneShield (ASX:DRO): -5%, AU$2.16EQ Resources (ASX:EQR): -5%, AU$0.31Block(ASX:XYZ): -4%, AU$113.35Zip (ASX:ZIP): -4%, AU$2.84Brazilian Rare Earths (ASX:BRE): -4%, AU$4.30Macmahon Holdings (ASX:MAH): -3%, AU$1.00

ASX 200ASX:4DXASX:BREASX:DROASX:EIQASX:EQRASX:MAHASX:PYCASX:RMDASX:XYZASX:ZIP
Asia

ASX Biggest Gainers

Here are the ASX-listed companies with the biggest gains on Tuesday.DroneShield (ASX:DRO): +12%, AU$2.03MAAS Group Holdings (ASX:MGH): +11%, AU$5.52Almonty Industries CDI 1:1 (ASX:AII): +10%, AU$17.71EQ Resources (ASX:EQR): +10%, AU$0.29Phylogica (ASX:PYC): +9%, AU$1.99Life360 CDI 3:1 (ASX:360): +9%, AU$27.87COSOL Infrastructure (ASX:CQE): +8%, AU$2.76Electro Optic Systems (ASX:EOS): +8%, AU$7.51Benz Mining (ASX:BNZ): +7%, AU$4.15Megaport (ASX:MP1): +6%, AU$19.10

ASX 200ASX:360ASX:AIIASX:BNZASX:CQEASX:DROASX:EOSASX:EQRASX:MGHASX:MP1ASX:PYC
Asia

PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease

PYC Therapeutics (ASX:PYC) said it received Safety Review Committee approval in July to escalate dosing in the phase 1b part C multiple ascending dose study in polycystic kidney disease patients to the higher dose group of 2.4 milligrams per kilogram of its drug candidate PYC-003, according to a Wednesday Australian bourse filing.The company said it also received approval for an open-label extension of the ongoing study to enable continuous dosing of the drug candidate for a period of up to 24 months.It had AU$669 million of cash on hand as of June 30, per the filing.PYC Therapeutics' shares rose nearly 2% in recent trading on Wednesday.

ASX:PYC
Asia

Australian Shares Flat; NEXTDC Reports 11% Increase in Pro Forma Contracted Utilization

Australian shares were again flat on Tuesday after oil prices eased from a one-month high point on reports of potential de-escalation in the Middle East conflict.The S&P/ASX 200 Index was little changed to close at 8,793.30.Brent crude oil futures fell nearly 1% to trade around $88 per barrel. An Iranian official said the country had received a proposal from mediators for a 10-day ceasefire, Reuters reported. This was despite the Houthis in Yemen saying they would impose a naval blockade on major oil producer Saudi Arabia.Spot gold rose nearly 1% to $4,045.65 per ounce.On the domestic front, the ANZ-Roy Morgan Australian consumer confidence rose 0.3 points to 75.6 in the week of July 13 to July 19, ANZ reported.Australian consumer confidence edged higher last week, with improved sentiment around major household purchases largely offset by "weaker confidence in personal finances and the economic outlook," according to ANZ economist Sophia Angala.In company news, NEXTDC's (ASX:NXT) pro-forma contracted utilization increased 11% since April 20 to 740 megawatts as of June 30 following additional customer contract awards. The company's pro forma forward order book increased to 565 megawatts due to contract wins.Telix Pharmaceuticals (ASX:TLX) reported second-quarter revenue rose 21% to $247 million due to strong sale of precision medicine category. The company expects fiscal 2026 income to track in line with the upper end of the outlook of $950 million to $970 million.Lastly, PYC Therapeutics (ASX:PYC) said autosomal dominant optic atrophy (ADOA) patients in the ongoing clinical trials of its PYC-001 drug candidate showed sustained improvement in both visual acuity and retinal stress following repeat doses.

ASX 200ASX:NXTASX:PYCASX:TLX
Asia

Update: PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials; Shares Down 4%

(Updates with the stock movement in the headline and last paragraph)PYC Therapeutics (ASX:PYC) said autosomal dominant optic atrophy (ADOA) patients in the ongoing clinical trials of its PYC-001 drug candidate showed sustained improvement in both visual acuity and retinal stress following repeat doses, according to a Tuesday Australian bourse filing.Non-human primates treated with a single dose of the candidate at 15 micrograms per eye showed a sustained increase in OPA1 protein target gene expression in the retina four months after a single treatment.Human patients are currently receiving the candidate once every two to three months. The data from non-human primates support extending the dosing interval to once every four months or more. The firm plans to review the clinical protocol for the ongoing studies with a view to extending the dosing interval in these trials.Shares of PYC Therapeutics fell 4% in recent Tuesday trade.

ASX:PYC
Asia

PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials

PYC Therapeutics (ASX:PYC) said autosomal dominant optic atrophy (ADOA) patients in the ongoing clinical trials of its PYC-001 drug candidate showed sustained improvement in both visual acuity and retinal stress following repeat doses, according to a Tuesday Australian bourse filing.Non-human primates treated with a single dose of the candidate at 15 micrograms per eye showed a sustained increase in OPA1 protein target gene expression in the retina four months after a single treatment.Human patients are currently receiving the candidate once every two to three months. The data from non-human primates support extending the dosing interval to once every four months or more. The firm plans to review the clinical protocol for the ongoing studies with a view to extending the dosing interval in these trials.

ASX:PYC
Asia

PYC Therapeutics Starts Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease; Shares Up Nearly 5%

PYC Therapeutics (ASX:PYC) started a phase 1b multiple ascending dose study in patients with polycystic kidney disease, with the dosing of the first patient with its drug candidate, PYC-003, completed, according to a Thursday Australian bourse filing.The study will seek to determine the safety/tolerability profile and optimal repeat dosing regimen of PYC-003 before a proposed transition to a registrational combined phase 2/3 trial.It will also measure other endpoints, including urinary PC1 protein levels, total kidney volume on magnetic resonance imaging, and the estimated glomerular filtration rate, per the filing.The company's shares gained nearly 5% in recent Thursday trade.

ASX:PYC
Asia

PYC Therapeutics' Blinding Eye Disease Treatment Candidate Gets Orphan Drug Designation in Europe

PYC Therapeutics (ASX:PYC) said its VP-001 drug candidate for blinding eye disease Retinitis Pigmentosa type 11 received orphan drug designation from the European Medicines Agency, according to a Monday filing with the Australian bourse.The benefits of the designation include scientific advice and other assistance from the European regulator, lower regulatory fees for the drug candidate's review, and 10 years of exclusivity in the European market once approved.VP-001 previously obtained orphan drug designation and fast track status from the US Food and Drug Administration, PYC Therapeutics said.

ASX:PYC
Asia

PYC Therapeutics Advances Optic Atrophy Drug to Multiple-Dose Study After Safety Clearance; Shares Up 7%

PYC Therapeutics (ASX:PYC) has been cleared by the safety review committee to advance PYC-001 candidate into a multiple ascending dose study in patients with autosomal dominant optic atrophy (ADOA), following positive four-week safety and tolerability results from the 60 microgram single ascending dose trial, according to a Wednesday filing with the Australian bourse.The company is currently assessing repeat dosing in ADOA patients to evaluate safety and preliminary efficacy, aiming to establish clinical proof of concept before initiating a global registrational trial to support a new drug application, the filing said.The results from the ongoing phase one and two multiple ascending dose study will be presented throughout 2026 and 2027, the filing added.The company's shares rose 7% in recent Wednesday trade.

ASX:PYC

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:PYC in your portfolio
WheelAI
WheelAI
Analyze ASX:PYC options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:PYC